Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Michelle R Ryan Director |
SELL
Open market or private sale
|
Direct |
2,800
-20.54%
|
$165,200
$59.7 P/Share
|
|
Oct 30
2024
|
Michelle R Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+25.48%
|
-
|
|
Oct 30
2024
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+27.37%
|
-
|
|
Oct 30
2024
|
Stephanie Okey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+26.96%
|
-
|
|
Oct 30
2024
|
Michael J Barber Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+20.53%
|
-
|
|
Oct 30
2024
|
Frank A Damelio Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+26.96%
|
-
|
|
Oct 30
2024
|
Donald E Morel Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+6.24%
|
-
|
|
Oct 30
2024
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+12.47%
|
-
|
|
Oct 30
2024
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+11.22%
|
-
|
|
Oct 30
2024
|
Rolf A Classon Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+8.86%
|
-
|
|
Oct 30
2024
|
Jack L Stahl Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+8.86%
|
-
|
|
Oct 18
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
SELL
Open market or private sale
|
Direct |
320
-1.32%
|
$18,880
$59.97 P/Share
|
|
Sep 26
2024
|
David Mc Erlane Group President, Biologics |
SELL
Open market or private sale
|
Direct |
1,994
-5.21%
|
$117,646
$59.97 P/Share
|
|
Aug 02
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
662
-2.16%
|
$39,058
$59.56 P/Share
|
|
Aug 02
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
666
-1.65%
|
$39,294
$59.55 P/Share
|
|
Aug 02
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
SELL
Open market or private sale
|
Direct |
608
-2.44%
|
$35,872
$59.58 P/Share
|
|
Aug 02
2024
|
Lisa Evoli SVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
3,859
-8.93%
|
$227,681
$59.67 P/Share
|
|
Aug 02
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
1,169
-1.02%
|
$68,971
$59.55 P/Share
|
|
Jul 29
2024
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
9,088
-4.87%
|
$527,104
$58.76 P/Share
|
|
Jul 29
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
206
-0.67%
|
$11,948
$58.67 P/Share
|
|
Jul 29
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
283
-0.7%
|
$16,414
$58.69 P/Share
|
|
Jul 29
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
349
-0.3%
|
$20,242
$58.7 P/Share
|
|
Jul 26
2024
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
63,736
+44.36%
|
-
|
|
Jul 26
2024
|
Michael Hatzfeld Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,624
+29.36%
|
-
|
|
Jul 26
2024
|
David Mc Erlane Group President, Biologics |
BUY
Grant, award, or other acquisition
|
Direct |
18,746
+32.86%
|
-
|
|
Jul 26
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
17,042
+40.64%
|
-
|
|
Jul 26
2024
|
Lisa Evoli SVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,338
+26.19%
|
-
|
|
Jul 26
2024
|
Matti Masanovich SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,604
+35.78%
|
-
|
|
Jul 26
2024
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,671
+34.59%
|
-
|
|
Jul 26
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
10,225
+24.9%
|
-
|
|
Jul 26
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
11,078
+21.44%
|
-
|
|
Jul 26
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
18,746
+13.99%
|
-
|
|
Jul 08
2024
|
Matti Masanovich SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,993
-8.12%
|
$167,608
$56.74 P/Share
|
|
Jun 04
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
1,401
-6.36%
|
$75,654
$54.26 P/Share
|
|
Mar 15
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
387
-1.29%
|
$21,672
$56.2 P/Share
|
|
Jan 25
2024
|
Christa Kreuzburg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-2.78%
|
$26,150
$50.41 P/Share
|
|
Jan 16
2024
|
Michael Hatzfeld Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,908
+46.71%
|
-
|
|
Dec 08
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
250
-0.83%
|
$9,250
$37.18 P/Share
|
|
Dec 08
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,023
+3.28%
|
-
|
|
Dec 08
2023
|
Alessandro Maselli President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,924
-2.14%
|
$71,188
$37.18 P/Share
|
|
Dec 08
2023
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,761
+4.02%
|
-
|
|
Dec 08
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Payment of exercise price or tax liability
|
Direct |
367
-0.38%
|
$13,579
$37.18 P/Share
|
|
Dec 08
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
1,505
+1.53%
|
-
|
|
Dec 08
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Payment of exercise price or tax liability
|
Direct |
256
-1.15%
|
$9,472
$37.18 P/Share
|
|
Dec 08
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
747
+3.24%
|
-
|
|
Oct 27
2023
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+19.94%
|
-
|
|
Oct 27
2023
|
Michael J Barber Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+34.31%
|
-
|
|
Oct 27
2023
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+20.31%
|
-
|
|
Oct 27
2023
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+47.56%
|
-
|
|
Oct 27
2023
|
Karen Flynn Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+22.32%
|
-
|